Related Experiment Videos
Avinza - 24-h sustained-release oral morphine therapy.
1Radiant Research, Daytona Beach, FL 32114, USA.
Expert Opinion on Pharmacotherapy
|March 5, 2004
Summary
Avinza, a once-daily oral morphine, offers comparable pain relief to other formulations with reduced plasma fluctuations. It also improves sleep quality, particularly when taken in the morning, and is well-tolerated in osteoarthritis patients.
Area of Science:
- Pharmacology
- Pain Management
- Sleep Science
Background:
- Extended-release oral morphine formulations are crucial for managing chronic pain.
- Optimizing pharmacokinetic profiles can enhance therapeutic efficacy and patient compliance.
- Understanding the impact of dosing timing on sleep quality is important for pain management.
Purpose of the Study:
- To evaluate the pharmacokinetic profile and analgesic efficacy of Avinza, a once-daily extended-release oral morphine.
- To compare Avinza's efficacy and safety with other controlled-release morphine and oxycodone formulations.
- To assess the effect of Avinza on sleep quality and patient tolerability, including the impact of dosing time.
Main Methods:
- Pharmacokinetic analysis of plasma concentration fluctuations.
- Statistical comparison of analgesic efficacy against MS Contin, Oxycontin, and immediate-release oral morphine.
- Assessment of sleep quality using validated measures.
- Evaluation of side effect profiles and tolerability in patients with osteoarthritis.
Main Results:
- Avinza demonstrated a pharmacokinetic profile with less peak-to-trough plasma concentration fluctuation compared to other formulations.
- Analgesic efficacy of Avinza was statistically identical to controlled-release morphine sulfate (MS Contin), controlled-release oxycodone HCl (Oxycontin), and multiple doses of immediate-release oral morphine.
- Avinza significantly improved sleep quality, with greater benefits observed when administered in the morning versus at night.
- Common opioid side effects (constipation, nausea, somnolence) were observed. Doses of 30-60 mg/day were well-tolerated in elderly osteoarthritis patients who had failed other treatments.
Conclusions:
- Avinza provides effective and consistent analgesia with a favorable pharmacokinetic profile.
- Morning administration of Avinza may offer superior sleep improvement benefits.
- Avinza is a well-tolerated option for managing chronic pain, including in elderly osteoarthritis patients with inadequate relief from other medications.